Neurobridge IP Holdings

Neurobridge IP Holdings is a biotechnology company focused on the development of novel small molecule therapeutics for neuropsychiatric and neurological disorders. The company primarily manages and develops intellectual property related to next-generation NMDA receptor modulators designed to offer improved safety and efficacy profiles compared to existing treatments like ketamine. Their research efforts target high-unmet-need areas such as treatment-resistant depression and post-traumatic stress disorder. By leveraging a portfolio of proprietary chemical entities, Neurobridge aims to bridge the gap between early-stage discovery and clinical application in the mental health space.